2016
- June 2016, Youngene was founded in Zhangjiang Hi-Tech Industry Park, Shanghai, China
2017
- Initiated IND-enabling studies for YG1699
2018
- Completed IND-enabling studies for YG1699
- Obtained US FDA greenlight for YG1699 first-in-human study
2019
- Obtained China CFDA IND approval for YG1699
- YG1699 first-in-human/Phase I clinical trial initiated in the US
- Honored among China’s Top 100 New Drug Innovation Companies
2020
- Completed monkey study for YG1699 with T2DM+CKD model
- Completed Phase I trial for YG1699 in US
- YG1699 first-in-human trial results presented at ADA
2021
- Initiated YG1699 China Bridging study
- Initiated T1DM Phase 2a clinical study in the US for YG1699
- YG1699 kidney failure animal model study results presented at EASD
2022
- YG1699 T1DM Phase 2 Clinical Trial Completed
- YG1699 China Bridge Test Completed
- Announce YG1699 T1DM Phase 2 data in EASD
- YG1699's research plan in the field of heart failure has received FDA approval
- Participated in the American Heart Association (AHA) seminar and received positive feedback from participating experts
2023
- Initiate Heart Failure phase IIa study in the U.S.
- Initiate T2DM phase II/III study in China
- Initiate T1DM phase II/III study in the U.S.
- Initiate T2DM + Renal Failure phase II study in China